avelumab,paclitaxel,pelareorep
pfizer,merck,oncolytics biotech
['breast', 'bracelet-1']
early data from the phase ii bracelet-1 study indicates chemotherapy plus the oncolytic reovirus pelareorep has a higher response rate compared to chemotherapy alone for metastatic #breastcancer. dr. amy clark presented the study today at #asco23. 
We share clinical updates about the physicians and providers, research, programs and initiatives at @PennMedicine and @Penn's Perelman School of Medicine.